Special Issue

Small Molecule Drug Discovery with Anti-microbial and Anti-cancer Properties

Message from the Guest Editors

The journey of discovering effective treatments for infectious diseases and cancer has been a challenging and evolving process. Historically, drug discovery often relied on trial and error, resulting in lengthy and resource-intensive endeavors. However, the advent of computational methods has transformed this landscape, ushering in a new era of accelerated and targeted drug development. However, these traditional methods often yielded limited success due to the complex nature of diseases and the immense diversity of potential drug candidates. In the realm of modern drug design, computer-aided molecular modeling and simulation techniques stand as indispensable tools. They empower researchers to identify potential drug candidates with greater efficiency and precision than conventional experimental approaches. Topics of interest for this Special Issue may include, but are not limited to, natural product-derived antimicrobials and anticancer compounds, in silico screening of small molecules, molecular dynamics simulations in rational drug design, machine learning approaches for drug design, network pharmacology for drug discovery, and the structure-based design of PROTACs.

Guest Editors

Dr. Vikas Kumar

Basque Center for Materials, Applications, and Nanostructures (BCMaterials), Buil. Martina Casiano, Pl. 3 Parque Científico UPV/EHU Barrio Sarriena, 48940 Leioa, Spain

Dr. Shraddha Parate

Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden

Deadline for manuscript submissions

closed (31 October 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/182166

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).